OAI Nexus

Rare Disease Intelligence PlatformOAI Nexus

A rare disease intelligence platform connecting education, clinical research, and orphan drug innovation.

One place for everyone in the rare disease community: patients and families, physicians, researchers, and investors.

The first AI platform built for rare disease

Visit OAI Home PageSee the four tools

An interactive map of the rare disease landscape that all four Nexus tools draw on: 14 rare diseases including cystic fibrosis, Duchenne muscular dystrophy and myasthenia gravis, linked to the companies developing treatments for them and to those companies’ products, among them Vyvgart, Exondys 51 and Galafold. Companies working across more than one condition appear once, shared between them.

The four Nexus tools

Each tool is written for a different part of the rare disease community: families, physicians, researchers, and investors. All four use the same underlying data.

Nexus Intelligence

Search rare diseases, the companies working on them, and the products in development. Every record shows its source.

0
Diseases
0
Companies
0
Products
0
Links

Clinical Nexus

A rare disease research assistant for questions about mechanism, pathways, and clinical evidence.

Covers
Mechanism, pathways, evidence
Separates
Established from preliminary
Includes
Small cohorts and case reports
Sources
Flags anything it can't source

Patient Nexus

A rare disease diagnosis explained in plain language: what it is, what causes it, and what is being studied.

For education only. Use it to prepare questions for your doctor.

Nexus Diligence

A structured assessment of an orphan drug candidate, with any missing data flagged.

Scientific footing
Clinical outlook
Epidemiology
Pricing
Competition
Investment case

Rare disease has never had a general-purpose AI platform built for it.

Patients, clinicians, researchers, and the companies developing treatments all need different things. A family needs a diagnosis explained in language they can use. A physician or researcher needs a quick, well-sourced way through a literature that is scattered and thin. An investor or drug developer needs a structured view of whether a therapy is worth the money and years it will take.

Patient Nexus, Clinical Nexus, and Nexus Diligence are built for those groups, and all three draw on the same understanding of each disease. Nexus Intelligence sits underneath them: a searchable database of rare diseases, the companies working on them, and the products in development, built from the orphan drug pipeline and clinical trial records.

The platform is free to use and requires no account.

7,000–10,000
Rare diseases identified to date

Estimated range, NORD / EURORDIS

~72%
Believed to have a genetic origin

EURORDIS estimate

4–7 yrs
Average wait for an accurate diagnosis

Commonly reported across patient surveys

The four Nexus tools in detail

Nexus Intelligence

For anyone who wants to see the whole rare disease landscape in one place.

Who it’s for

Researchers, investors, clinicians, and patient advocates who want to explore what exists across rare disease rather than ask a single question about it.

What it does

Rare disease data is scattered across Orphanet, FDA orphan designations, Drugs@FDA, and ClinicalTrials.gov, and none of those talk to each other. Nexus Intelligence joins them into one browsable map of 63,433 disease-company-product links you can filter, group, and export however you want. Every record shows its source and how confidently it was matched, so you can check where it came from.

Enter Nexus Intelligence

Patient Nexus

For patients and families who want a diagnosis explained in plain language.

Who it’s for

Patients and families who want a rare disease explained in everyday language, without medical jargon.

What it does

Most rare disease information online is written for clinicians. Patient Nexus explains a condition, its genetics, and its treatment options in plain language, and says clearly when something is uncertain. It does not diagnose or give advice about specific symptoms. It can help you prepare questions for your own doctor.

Enter Patient Nexus

Clinical Nexus

For physicians, researchers, and students who need fast, well-sourced answers about rare disease.

Who it’s for

Physicians, researchers, and students working with rare disease literature and disease mechanisms.

What it does

Rare disease research is spread across small cohorts, case reports, and trials that rarely come up in a standard search. Clinical Nexus answers questions about mechanism, pathways, clinical evidence, and open questions. It separates established findings from preliminary and contested ones, and says so when it has no reliable source instead of making one up.

Enter Clinical Nexus

Nexus Diligence

For investors, biotech teams, and drug developers evaluating an orphan drug candidate.

Who it’s for

Investors, biotech teams, and drug developers who need a structured evaluation of an orphan drug candidate before committing money or resources.

What it does

Assessing a rare disease therapy means weighing science, regulation, epidemiology, and pricing together, and rare disease markets behave differently from the rest of pharma. Nexus Diligence takes a profile of a candidate and returns a structured assessment covering the science, clinical outlook, market size, pricing, competition, and the investment case for and against. Missing or uncertain data is flagged, not estimated away.

Enter Nexus Diligence

Frequently asked questions

What is OAI Nexus?
OAI Nexus is the first AI platform built specifically for rare disease. It has four modules: Nexus Intelligence, a searchable map of rare diseases, companies, and products in development; Patient Nexus for patient education; Clinical Nexus for research; and Nexus Diligence for drug evaluation.
Is OAI Nexus the first rare disease AI platform?
Yes, OAI Nexus is believed to be the first publicly available AI platform purpose-built for rare disease, not a general medical AI adapted for rare disease.
Who is OAI Nexus for?
OAI Nexus serves patients and families seeking rare disease education, physicians and researchers needing clinical evidence, and biotech investors and professionals evaluating orphan drugs. Nexus Intelligence serves all three by making the underlying landscape searchable.
What are the four modules of OAI Nexus?
Nexus Intelligence is a browsable database of rare diseases, companies, and products in development. Patient Nexus is for patient education, Clinical Nexus is for research professionals, and Nexus Diligence is for biotech and investment due diligence on orphan drugs.
Is OAI Nexus free to use?
Yes, OAI Nexus is free and accessible to patients, clinicians, researchers, students, and biotech professionals working in rare disease.
How many people use OAI Nexus?
OAI Nexus has reached 10,000 users: researchers, investors, clinicians, and patient advocates worldwide, searching across 11,645 rare diseases, 7,851 companies, and 23,883 products in development. OAI Nexus is free to use and requires no account.
What data does Nexus Intelligence cover?
Nexus Intelligence joins Orphanet disease definitions, FDA orphan drug designations, Drugs@FDA approvals, and ClinicalTrials.gov records into 63,433 disease-company-product links. Every row carries the source and match confidence it came from, so you can trace where a claim originates.
What is an orphan drug?
An orphan drug is a medication developed to treat a rare disease or condition. In the US, a disease is considered rare if it affects fewer than 200,000 people.
What is the Orphan Access Initiative?
The Orphan Access Initiative is a student-led research organization that built OAI Nexus to understand why promising treatments don't reach rare disease patients.